The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | The importance of reporting real world data in myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, talks on the importance of reporting real-world data on the treatment of multiple myeloma. Dr Cerchione discusses how real-world data can be used to confirm safety and efficacy outcomes demonstrated in clinical trials, as well as enabling the assessment of therapies in subgroups of patients who are not eligible for registration in clinical trials. Dr Cerchione highlights real-world data on carfilzomib-lenalidomide-dexamethasone, bendamustine-bortezomib-dexamethasone and pomalidomide-dexamethasone in patients with relapsed/refractory myeloma, and comments on the need for real-world data registries. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
